Cancer Deaths Drop But New Cases Rise in Unexpected Ways

The Good News That Came With a Catch

In 1991, cancer killed more Americans than ever before. The toll was staggering: 215 deaths per 100,000 people. Then something shifted. Not overnight, not by accident, but through decades of smoking cessation campaigns, earlier detection technologies, and treatments that finally started working. By 2021, the death rate had fallen by 33 percent. That translates to roughly 4 million deaths averted since the peak. It is the kind of public health victory that deserves a parade.

But here is the part that keeps oncologists up at night.

While the death rate keeps dropping, the number of new cancer cases is rising. And not just in the ways you might expect. According to the American Cancer Society's latest annual report, led by Rebecca L. Siegel and her colleagues at the ACS, the United States is projected to hit 2,001,140 new cancer cases in 2024 (Siegel et al., 2024). That is the first time the estimate has crossed the two million threshold. Meanwhile, the authors project 611,720 cancer deaths for the same year (Siegel et al., 2024). The gap between new diagnoses and deaths is widening. But that widening gap is not a simple story.

To understand why, you have to look at which cancers are rising, who is getting them, and why the old rules no longer apply.

The Numbers That Should Not Be Moving This Way

Six of the top ten cancers are climbing

The report, published in CA: A Cancer Journal for Clinicians, compiles incidence data from central cancer registries through 2020 and mortality data from the National Center for Health Statistics through 2021. It is the most comprehensive snapshot of the country's cancer burden available.

Here is what Siegel and her team found: during the period from 2015 to 2019, incidence rates for six of the ten most common cancers increased. The increases ranged from modest to alarming.

• ▸Breast, pancreas, and uterine corpus cancers rose by 0.6 to 1 percent annually.
• ▸Prostate, kidney, and liver cancer in women, along with melanoma and HPV associated oral cancers, rose by 2 to 3 percent annually (Siegel et al., 2024).

These are not rounding errors. A 2 to 3 percent annual increase compounds. Over a decade, that means a 20 to 30 percent higher risk of getting those cancers compared to a population with stable rates.

The young adult problem

The most unsettling finding is not in the elderly, where cancer has always been most common. It is in people under 50.

Colorectal cancer incidence increased by 1 to 2 percent annually in adults younger than 55 (Siegel et al., 2024). Cervical cancer, which had been declining for decades thanks to screening and HPV vaccines, is now rising by 1 to 2 percent annually in women aged 30 to 44 (Siegel et al., 2024).

Here is the statistic that should make every young person pay attention: in the late 1990s, colorectal cancer was the fourth leading cause of cancer death in both men and women under 50. Today, it is the leading cause of cancer death in young men and the second leading cause in young women (Siegel et al., 2024). That is not a slow drift. That is a generational shift happening in real time.

Why Deaths Are Dropping While Cases Are Rising

The treatment revolution

The decline in cancer mortality is real and it is accelerating. Between 2019 and 2020, the overall death rate dropped by 1.5 percent. Between 2020 and 2021, it dropped by 1.9 percent (Siegel et al., 2024). The authors attribute this to three main factors: reductions in smoking, earlier detection for some cancers, and improved treatment options in both the adjuvant and metastatic settings (Siegel et al., 2024).

That last part matters enormously. We are living through a golden age of cancer therapeutics. Immunotherapies that unleash the immune system against tumors. Targeted therapies that attack specific genetic mutations. Combination regimens that turn previously fatal cancers into chronic diseases. These treatments are saving lives, even among patients with advanced disease.

But here is the uncomfortable truth: better treatment does not prevent cancer from occurring in the first place. It only manages the damage after it happens.

The detection paradox

Some of the rising incidence is actually good news. More screening means more cancers caught early, which inflates the incidence numbers while simultaneously driving down mortality. This is particularly true for prostate cancer, where PSA testing can identify tumors that might otherwise go undiagnosed.

But the authors are careful to note that not all of the increase can be explained by better detection. The rise in pancreatic cancer, for example, has no screening explanation. Neither does the rise in uterine corpus cancer or liver cancer in women. These are real increases in disease occurrence, not artifacts of surveillance.

The Cancers That Are Behaving Differently

Colorectal cancer: the young adult epidemic

The colorectal cancer story deserves its own section because it is the clearest example of something new happening.

Colorectal cancer has traditionally been a disease of aging. The median age at diagnosis is 66. But the incidence in people under 55 has been rising steadily since the mid 1990s. The authors found that the increase accelerated during the study period, with annual increases of 1 to 2 percent in young adults (Siegel et al., 2024).

Nobody knows exactly why. The leading hypotheses involve changes in the gut microbiome, increased consumption of ultra processed foods, rising obesity rates, and sedentary behavior. But none of these explanations fully account for the pattern. What is clear is that the disease behaves differently in young people. They tend to present with more aggressive tumors, often at later stages, partly because nobody suspects colorectal cancer in a 35 year old.

Cervical cancer: the vaccine gap

Cervical cancer was supposed to be on its way out. The HPV vaccine, introduced in 2006, prevents infection with the strains that cause most cervical cancers. Screening with Pap smears catches precancerous lesions before they become invasive. For decades, incidence and mortality both declined.

But the authors found that cervical cancer incidence is now rising by 1 to 2 percent annually in women aged 30 to 44 (Siegel et al., 2024). This is likely a cohort effect. Women in this age group were born between 1980 and 1994. They were too old to receive the HPV vaccine when it was introduced, and they may have been less likely to receive regular screening than older generations who grew up with Pap smears as a routine part of women's health.

The message is clear: the vaccine works, but only if people actually get it. And screening works, but only if people actually do it.

Uterine corpus cancer: the overlooked epidemic

Uterine corpus cancer, which includes endometrial cancer, is rising by about 1 percent annually (Siegel et al., 2024). This is less dramatic than the increases in prostate or colorectal cancer, but it is deeply concerning because uterine cancer has no routine screening test. By the time it causes symptoms like abnormal bleeding, it may already be advanced.

The rise is linked to obesity, which increases estrogen levels and fuels endometrial growth. As obesity rates have climbed in the United States, so has uterine cancer. The disparity is stark: Black women are more likely to die from uterine cancer than White women, despite having similar incidence rates (Siegel et al., 2024). This suggests differences in access to care, treatment quality, or tumor biology.

Who Is Dying and Why

The persistence of racial disparities

The report documents what every oncologist already knows but nobody has fully fixed: cancer does not kill everyone equally.

Compared to White people, mortality rates are two times higher for prostate, stomach, and uterine corpus cancers in Black people (Siegel et al., 2024). For liver, stomach, and kidney cancers, mortality is two times higher in Native American people (Siegel et al., 2024).

These disparities are not genetic. They are structural. Black and Native American populations have less access to preventive care, lower rates of cancer screening, longer delays between diagnosis and treatment, and higher exposure to environmental carcinogens. They are also less likely to receive the latest treatments, even when they have insurance.

The authors put it bluntly: continued national progress will require increased investment in cancer prevention and access to equitable treatment, especially among American Indian and Alaska Native and Black individuals (Siegel et al., 2024).

The geography of death

Cancer mortality also varies dramatically by region. Death rates are highest in the South and in parts of Appalachia, where smoking rates are higher, obesity is more common, and healthcare access is limited. They are lowest in the Northeast and on the West Coast, where public health infrastructure is stronger and screening rates are higher.

This is not a mystery. It is a policy failure.

What This Research Does Not Prove

The open questions

The Siegel report is descriptive, not explanatory. It tells us what is happening but not always why. Here are the questions the data raise but do not answer.

First, why is colorectal cancer rising in young people? The authors note the correlation with obesity and dietary changes, but correlation is not causation. There may be environmental exposures, microbiome shifts, or epigenetic changes that we have not yet identified.

Second, will the rise in incidence eventually overwhelm the decline in mortality? If more people are getting cancer, even if fewer are dying from it, the absolute number of deaths could eventually start rising again. The authors do not model this scenario, but the math is straightforward.

Third, how will the COVID 19 pandemic affect future cancer statistics? The data in this report only go through 2020 for incidence and 2021 for mortality. Millions of people delayed cancer screenings during the pandemic. The cancers that would have been caught early are now being diagnosed later, at more advanced stages. The full impact will not be visible for several more years.

Fourth, can the disparities be closed without systemic change? The report calls for increased investment in prevention and equitable treatment. But the history of cancer disparities suggests that incremental improvements are not enough. Structural racism, poverty, and geographic isolation require structural solutions.

How the Study Was Done

The methodology matters

The American Cancer Society has been producing these annual reports since the 1960s. The methodology is rigorous and consistent.

For incidence data, the authors used the National Cancer Institute's Surveillance, Epidemiology, and End Results program, along with the Centers for Disease Control and Prevention's National Program of Cancer Registries. These registries cover essentially the entire United States population. For mortality data, they used the National Center for Health Statistics, which collects death certificates from every state.

The projections for 2024 are based on statistical models that extrapolate from historical trends. They are estimates, not predictions carved in stone. But they are the most reliable estimates available, and they have been accurate in previous years.

The authors also stratified their analysis by age, sex, race, and geographic region. This allowed them to identify the disparities and trends that a national average would obscure.

What This Actually Means

• ▸If you are under 50 and have digestive symptoms that persist for more than a few weeks, do not let a doctor dismiss them as hemorrhoids or irritable bowel syndrome. Colorectal cancer is now the leading cause of cancer death in young men and the second leading cause in young women. The standard of care for young adults with concerning symptoms should include a colonoscopy, not just reassurance.

• ▸The HPV vaccine is not just for children. Women in their 30s and 40s who missed the vaccine can still benefit from it, and they should discuss it with their doctor. More importantly, cervical cancer screening remains essential even for vaccinated women, because the vaccine does not cover all cancer causing strains.

• ▸Obesity is not just a heart disease risk factor. It is driving increases in uterine, breast, pancreatic, and colorectal cancers. The relationship between body weight and cancer risk is dose dependent and well established. Weight management is cancer prevention.

• ▸If you are Black or Native American, the system is failing you. The mortality disparities documented in this report are not inevitable, but they will not close without deliberate action. That means pushing for better insurance coverage, demanding screening access in underserved communities, and supporting policies that address the social determinants of health.

• ▸The decline in cancer mortality is real and it is accelerating. But it is not a reason for complacency. The treatments that are saving lives are expensive, and they do not prevent cancer from occurring. The next frontier is prevention: understanding why incidence is rising and doing something about it before people get sick.

The paradox of modern cancer care is that we have never been better at treating the disease, but we have never been worse at preventing it. The Siegel report is a warning dressed up as good news. The mortality numbers give us hope. The incidence numbers give us homework.